Matt Browne

Cooley advised MannKind, a company focusing on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases, on the sale of a 1% royalty in net sales of Tyvaso DPI (treprostinil) inhalation powder to Sagard Healthcare for up to $200 million.

Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.

Cooley represented Shoreline Biosciences, a biotechnology company developing cellular immunotherapies, on its $140 million financing led by Ally Bridge Group. Partner Tom Coll led the Cooley team.

Cooley advised global investment firm Sixth Street on its strategic investment in Blueprint Medicines, a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Lawyers Mischi a Marca, Matt Browne, Matt Scarano, Addison Pierce, Matt Kong and Nick Neuteufel led the Cooley team advising Sixth Street. 

Cooley advised Billtrust, a leading provider of cloud-based software and integrated payment processing solutions that simplify and automate B2B commerce, on its agreement to combine with South Mountain Merger Corporation, a publicly traded special purpose acquisition company or SPAC. The combined company will continue as a publicly listed entity and have an implied estimated enterprise value of approximately $1.3 billion at closing. Partners Miguel Vega, Nicole Brookshire and Matt Browne led the Cooley team advising Billtrust.